Last update 12 Mar 2025

Ipilimumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti CTLA-4 monoclonal antibody, Anti-CTLA-4 Mab, Ipilimumab (Genetical Recombination)
+ [16]
Target
Mechanism
CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (25 Mar 2011),
RegulationBreakthrough Therapy (US), Fast Track (US), Orphan Drug (US), Priority Review (CN), Breakthrough Therapy (CN), Conditional marketing approval (CN), Orphan Drug (KR), Priority Review (AU), Priority Review (US), Accelerated Approval (US)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D04603Ipilimumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Advanced Hepatocellular Carcinoma
EU
08 Mar 2025
Advanced Hepatocellular Carcinoma
IS
08 Mar 2025
Advanced Hepatocellular Carcinoma
LI
08 Mar 2025
Advanced Hepatocellular Carcinoma
NO
08 Mar 2025
Unresectable Hepatocellular Carcinoma
EU
08 Mar 2025
Unresectable Hepatocellular Carcinoma
IS
08 Mar 2025
Unresectable Hepatocellular Carcinoma
LI
08 Mar 2025
Unresectable Hepatocellular Carcinoma
NO
08 Mar 2025
Mismatch repair-deficient Colonic Cancer
EU
13 Jan 2025
Mismatch repair-deficient Colonic Cancer
IS
13 Jan 2025
Mismatch repair-deficient Colonic Cancer
LI
13 Jan 2025
Mismatch repair-deficient Colonic Cancer
NO
13 Jan 2025
Unresectable Esophageal Squamous Cell Carcinoma
US
27 May 2022
Esophageal Carcinoma
JP
26 May 2022
Mesothelioma
JP
27 May 2021
Mesothelioma
JP
27 May 2021
Hepatocellular Carcinoma
US
10 Mar 2020
Colorectal Cancer
US
16 Apr 2018
Advanced Renal Cell Carcinoma
EU
13 Jul 2011
Advanced Renal Cell Carcinoma
IS
13 Jul 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bladder CancerPhase 3
US
30 Jan 2022
Bladder CancerPhase 3
US
30 Jan 2022
HER2 negative Gastric CancerPhase 3
JP
05 Nov 2021
HER2 negative Gastric CancerPhase 3
KR
05 Nov 2021
HER2 negative Gastric CancerPhase 3
TW
05 Nov 2021
GlioblastomaPhase 3
US
01 Sep 2020
GliosarcomaPhase 3
US
01 Sep 2020
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
US
08 Oct 2019
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
CN
08 Oct 2019
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
JP
08 Oct 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
105
(Arm 1: Nivolumab)
twjrjzpcoy(riosgezojt) = fxiajywwwr lgytukdycu (dwcrpsftjs, ujxqljpqth - drewimsshz)
-
11 Mar 2025
(Arm 2: Nivolumab Plus Ipilimumab)
twjrjzpcoy(riosgezojt) = ggxerankzd lgytukdycu (dwcrpsftjs, elqfshgyvq - oldfiakxsf)
Phase 2
101
(Arm A - Nivolumab)
szrejwpgzk(hqhfftsfmt) = wwyizbqava dqxctkscgp (hajcczlhwp, kdxbcyzwmu - dhhkgluthf)
-
05 Mar 2025
(Arm B - Nivolumab + Ipilimumab)
szrejwpgzk(hqhfftsfmt) = ypdduwexda dqxctkscgp (hajcczlhwp, qhvnxyoqcz - eamijaprtf)
Not Applicable
Metastatic Renal Cell Carcinoma
Maintenance | First line
222
Four Doses of IPI + NIVO
zdbpnujvlm(kfdpypmdas) = refhxyoiaa nktwqlwcby (yxtlwqkcas, 82 - 93)
Positive
13 Feb 2025
Fewer Than Four Doses of IPI + NIVO
zdbpnujvlm(kfdpypmdas) = dnzidvlfcu nktwqlwcby (yxtlwqkcas, 72 - 94)
Phase 1/2
-
Nivolumab
thduzmybae(pdamcfritg) = hhtoqsvcha luwutvgdqj (jleipbwtdh, 38.7 - 78.9)
Negative
31 Jan 2025
Nivolumab + Ipilimumab
thduzmybae(pdamcfritg) = kzozmkmnxz luwutvgdqj (jleipbwtdh, 42.1 - 73)
Phase 2
17
darwfrnxrt(tkxchynwvf) = wgujmczruc lgqnasuesp (iotcsuozjp, kcemaqmozf - jmgfpokech)
-
30 Jan 2025
Phase 3
Microsatellite instability-high colorectal cancer
Second line | First line
MSI-High | Deficient DNA Mismatch Repair (dMMR)
703
bnhyryvaib(xtomintlvh) = pitaqgcaat rlbwnotdib (qpfqnjnfkf, 53.8 - NE)
Met
Superior
27 Jan 2025
bnhyryvaib(xtomintlvh) = vhafbpxvla rlbwnotdib (qpfqnjnfkf, 22.1 - NE)
Met
Phase 3
668
ogbqqlvgmg(ouizpxpqfm) = edkqmijzlm pckydzotkk (ufedlvkkte, 31 - 42)
Positive
23 Jan 2025
Lenvatinib/sorafenib
ogbqqlvgmg(ouizpxpqfm) = fevvwdyqnh pckydzotkk (ufedlvkkte, 10 - 17)
Phase 2
Pancreatic Cancer
BRCA2 Mutation | BRCA1 Mutation
32
bhxpkijabp(jagrvdbwgi) = hgqocfnsfe ghqcjdxijj (dlnvfovzij, 18 - 100)
Positive
23 Jan 2025
Phase 2
20
(Combination Nivolumab and Ipilimumab - Primary)
fyvznkeprc(dknvlgylhj) = xvtkbuyqkt xcbogprhow (xllsfqjrij, fseimfdwen - cxbeurougd)
-
09 Jan 2025
(Combination Nivolumab and Ipilimumab - Acquired)
fyvznkeprc(rfchjlkdce) = sufpbnyfxf jpkfdepuju (stoaaeffjg, ufgcdtedta - kpbekcubpo)
Phase 1
54
(Arm A (Decitabine, Ipilimumab), Post Allo-HCT, Dose Level 0)
xgnbgpuyis(vvibnckoco) = qfwmlqzqvg mpskeamieo (ffrhmktpia, cmgjuktsuo - jprizeytfw)
-
07 Jan 2025
(Arm B (Decitabine, Ipilimumab), Transplant Naive, Dose Level 0)
xgnbgpuyis(vvibnckoco) = kyogxsruzm mpskeamieo (ffrhmktpia, dmxzykxjrz - lqsfrmosdw)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free